Pharmaceutical developers are increasingly defending market position through proprietary drug delivery vectors rather than active pharmaceutical ingredients alone. The tactical pivot comes as patent protections on foundational mRNA technologies near expiration.
Regulatory Scrutiny on Delivery IP
Regulators are scrutinizing broad patent claims surrounding lipid nanoparticle formulations, forcing drugmakers to provide detailed bio-distribution safety profiles. Industry analysts anticipate an uptick in strategic cross-licensing agreements over the next 24 months.